Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

BACKGROUND: The randomized, double-blind, phase 3 ASPECT-NP trial evaluated the efficacy of 3 g of ceftolozane/tazobactam (C/T) versus 1 g of meropenem infused every 8 h for 8 to 14 days for treatment of adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shorr, Andrew F., Bruno, Christopher J., Zhang, Zufei, Jensen, Erin, Gao, Wei, Feng, Hwa-Ping, Huntington, Jennifer A., Yu, Brian, Rhee, Elizabeth G., De Anda, Carisa, Basu, Sumit, Kollef, Marin H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487337/
https://www.ncbi.nlm.nih.gov/pubmed/34600585
http://dx.doi.org/10.1186/s13054-021-03773-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487337/
https://www.ncbi.nlm.nih.gov/pubmed/34600585
http://dx.doi.org/10.1186/s13054-021-03773-5

Ejemplares similares